AMAR’s development partners are Hayashibara Biochemical Laboratories, Nobel, CytoPharm, Bumimedic, CytoBiotech and Intas Pharma.  Contact information for each partner is provided below along with a brief summary of the activities of each.

Hayashibara Biochemical Laboratories, Inc.

2-3 Shimoishii 1-chome Okayama 700, Japan

In its world-class facilities, Hayashibara makes the interferon lozenges that AMAR and its other development partners are testing.

Nobel Ilac

Sanayii Ve Ticaret A.S. Barbaros Bulvari 76/78 Besiktas 34353 Istanbul, Turkey

Nobel has a license and supply agreement for Turkey and most of Central Asia.

CytoPharm, Inc.

6^th Fl., No.6, Sec 1, Jungshing Road Wugu Shiang, Taipei County 248 Taiwan

CytoPharm has a license and supply agreement for Taiwan and China. CytoPharm has an ongoing Phase 2 study in Taiwan aimed at prevention of relapse in 165 patients chronically infected with the hepatitis C virus.

Bumimedic (Malaysia)

Sdn. Bhd. No. 3, Jalan 19/1, 16300 Petaling Jaya, Selangor, Malaysia

Bumimedic has a license and supply agreement for Malaysia.

CytoBiotech, Inc.

6F., No.6, Sec.1, Jhongshing Rd.,Wugu Shiang, Taipei county 24872, Taiwan

CytoBiotech has a license and supply agreement for Cambodia, Indonesia, the Philippines, Thailand, and Vietnam, as well as China, Taiwan and Malaysia, for those indications not licensed to CytoPharm or Bumimedic.

Intas Pharma

Chinubhai Center, Off Nehru Bridge, Ashram Road, 380 009, Gujarat, India

Intas has a license and supply agreement for India and Nepal. Intas plans to launch a double-blind, placebo-controlled influenza treatment study with oral IFN in 2010.